H.C. Wainwright reiterates USD 18.00 target for Gyre Therapeutics stock

Published on 10/20/2026 at 21:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 29.11 million on June 30, 2026. Gyre Therapeutics stock costs EUR 5.63 on October 20, 2026 at 9:01 p.m. CEST.

Target and latest figures

H.C. Wainwright reiterated a USD 18.00 target for Gyre Therapeutics on October 6, 2026.
Second-quarter 2026 revenue reached USD 29.11 million versus USD 26.49 million expected.
Gyre Therapeutics stock costs EUR 5.63 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST.

GYRE, US4037831033, Illustration mit AI erstellt.

H.C. Wainwright reiterated a Buy rating and a USD 18.00 price target for Gyre Therapeutics on October 6, 2026, giving the biotechnology stock a fresh analyst benchmark. According to The Globe and Mail, analyst Matthew Keller maintained the Buy view and target. Gyre Therapeutics stock was trading at EUR 5.63 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST.

What do the latest results show?

The latest reported quarter ended June 30, 2026, with revenue of USD 29.11 million. The figure exceeded the USD 26.49 million consensus cited by The Cerbat Gem, while GAAP earnings per share came in at minus USD 0.12 against consensus of minus USD 0.06. Revenue therefore beat expectations even as the per-share loss was wider than forecast.

Nasdaq range remains wide

On the Nasdaq, Gyre Therapeutics was last quoted at USD 6.30 on October 20, 2026 at 3:04 p.m. ET. The same session data place the stock's 52-week range at USD 5.44 to USD 9.14, while volume stood at 46,218 shares. The market capitalization was USD 667.7 million.

The Nasdaq quote puts the stock USD 2.84 below its 52-week high and USD 0.86 above its 52-week low. Those levels frame the analyst target, but the target is denominated in USD and remains separate from the euro quotation used for German-market readers.

Pipeline valuation meets execution risk

Gyre develops small-molecule treatments for inflammation and fibrosis. Its lead commercial medicine is ETUARY, while F351 is being studied for liver fibrosis. The latest quarter combines a revenue beat with a net loss of USD 14.27 million, making sales progression and clinical execution the two measurable reference points for the current valuation.

Euro quote after hours

After hours in Berlin, Gyre Therapeutics stock stood at EUR 5.63 at Lang & Schwarz on October 20, 2026 at 9:01 p.m. CEST. The Nasdaq quotation was separately USD 6.30 at 3:04 p.m. ET on the same date.

The further course of trading is shown by the continuously updated real-time quote of Gyre Therapeutics stock.